<DOC>
	<DOCNO>NCT00907998</DOCNO>
	<brief_summary>The design study enable extensive evaluation safety , tolerability , PK-PD relationship follow 4 week dose patient Coronary heart Disease</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics APL180</brief_title>
	<detailed_description />
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<criteria>Male female CHD CHD equivalent patient Body mass index ( BMI ) must within range 20 35 kg/m2 , Patient must stable statin therapy &gt; 8 week prior first dose except statin intolerant patient . Exclusion criterion : Pregnancy Significant illness within two week prior dose . Triglycerides â‰¥ 500 mg/dl ( 5.65 mmol/l ) Uncontrolled hypertension Any condition opinion investigator Novartis medical monitor would jeopardize evaluation efficacy safety . Presence NYHA Class III IV chronic heart failure MI angioplasty ( include stenting ) , acute coronary syndrome ( ACS ) , unstable angina arterial embolic disease within 6 month prior Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Coronary heart disease</keyword>
	<keyword>APL180</keyword>
</DOC>